此次爆发由罕见的Bundibugyo病毒株引起，主要透过接触受感染者的血液和体液传播。由于当地武装冲突、大规模人口流离失所，以及脆弱的医疗基础设施，世界卫生组织等医疗机构的防疫工作受到严重阻碍。
尽管目前尚未有可立即使用的疫苗，但针对Bundibugyo病毒株的首批两种疫苗（由Moderna和牛津大学开发）已开始进行第一期人体安全试验。专家表示，未来若能成功部署有效疫苗，将能大幅改变应对疫情的动态与成效。（关键数字：1）
The Democratic Republic of Congo is experiencing its deadliest Ebola outbreak in history, with the death toll reaching 2,325. The World Health Organization has warned of an intense transmission phase, noting that the actual number of infections could be up to five times higher than the officially reported 4,945 cases.
This outbreak is driven by the rare Bundibugyo strain of the Ebola virus, transmitted through direct contact with infected bodily fluids. Containment efforts by global health agencies are being severely hindered by ongoing armed conflicts, significant population displacement, and the country's fragile healthcare system.
Although no vaccines are available for immediate deployment, the first two vaccines specifically targeting the Bundibugyo strain, developed by Moderna and the University of Oxford, have entered phase 1 human trials. Experts emphasize that the eventual rollout of an effective vaccine will be crucial in changing the trajectory of the response.